Franklin Resources’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Franklin Resources’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,294,656	Closed	-$49.7M	–	2839
2023 Q2	$49.7M	Sell	1,294,656 -17,502	-1%	-$449K	0.02%	524
2023 Q1	$30.4M	Buy	+1,312,158	New	+$31.3M	0.02%	665
2016 Q2	–	Sell	-178,642	Closed	-$11.4M	–	1561
2016 Q1	$11.4M	Buy	178,642 +1,105	+0.6%	+$89.4K	0.01%	943
2015 Q4	$25M	Sell	177,537 -98,281	-36%	-$13.3M	0.01%	767
2015 Q3	$25.6M	Buy	275,818 +45,693	+20%	+$5.44M	0.01%	771
2015 Q2	$34.9M	Buy	+230,125	New	+$38M	0.02%	732

Franklin Resources's KDNY Position: Q3 2023 in Review

Franklin Resources sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 1,294,656 shares — an estimated $49.7M sold.

Franklin Resources first reported a position in KDNY in Q2 2015 and held it in 6 quarters. The position peaked at $49.7M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Franklin Resources reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Franklin Resources sold 1,294,656 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $49.7M.
Franklin Resources first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 6 quarters.
Franklin Resources's Chinook Therapeutics, Inc. Common Stock position peaked at $49.7M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Franklin Resources's 13F filing for Q3 2023, filed 13 Nov 2023.